天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Dacomitinib (PF299804, PF299),Dacomitinib (PF299804, PF299)
  • Dacomitinib (PF299804, PF299),Dacomitinib (PF299804, PF299)

1110813-31-4Dacomitinib (PF299804, PF299)

價格 詢價
包裝 1盒
最小起訂量 1盒
發(fā)貨地 上海
更新日期 2024-12-23
QQ交談 微信洽談

產(chǎn)品詳情

中文名稱:Dacomitinib (PF299804, PF299)英文名稱:Dacomitinib (PF299804, PF299)
CAS:1110813-31-4品牌: 一研
保存條件: Store at -20°C產(chǎn)品類別: 抑制劑
Cas : 1110813-31-4
2024-12-23 Dacomitinib (PF299804, PF299) Dacomitinib (PF299804, PF299) 1盒/RMB 一研 Store at -20°C 抑制劑

產(chǎn)品屬性:

產(chǎn)品名稱

規(guī)格

CAS

型號

Dacomitinib (PF299804, PF299)

10mM (in 1mL DMSO) 5mg 25mg

1110813-31-4

EY-Y0165484

Cas No.1110813-31-4

別名 PF-00299804; PF-299804; PF 299804; PF 00299804

化學(xué)名 (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide

分子式 C24H25ClFN5O2

Dacomitinib (PF299804, PF299).png

分子量 469.94

溶解度 23.5mg/mL in DMSO, 8.76 mg/mL in EtOH with ultrasonic and warming

儲存條件 Store at -20°C
General tips  For obtaining a higher solubility , please warm the tube at 37 and shake it in the ultrasonic bath for a while.
Shipping Condition     Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述:
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. Dacomitinib (PF-00299804) is an irreversible small molecule pan-HER inhibitor.

In vitro: Dacomitinib reduced the phosphorylation of HER2, EGFR, HER4, AKT, andERKin the majority of sensitive lines. Dacomitinib exerted its antiproliferative effect through a combined G0–G1 arrest and an induction of apoptosis. Dacomitinib inhibited growth in several HER2-amplified lines with de novo and acquired resistance to trastuzumab. Dacomitinib maintained a high activity in lines with acquired resistance to lapatinib. This study identifies HER2-amplified breast cancer lines as most sensitive to the antiproliferative effect of dacomitinib and provides a strong rationale for its clinical testing in HER2-amplified breast cancers resistant to trastuzumab and lapatinib [1].

In vivo: To evaluate the in vivo efficacy of PF00299804, the authors generated xenografts in nu/nu mice using HCC827 GFP and HCC827 Del/T790M cells and treated the mice with PF00299804. PF00299804 effectively inhibited the growth of HCC827 GFP xenografts. PF00299804 treatment was substantially more effective at inhibiting growth of this xenograft model than gefinitib. Thus, these preclinical models suggest that PF00299804 may be quite effective against lung cancers that become resistant to gefitinib or erlotinib via acquisition of a T790M mutation in EGFR [2].

Clinical trial: Dacomitinib (PF-00299804) is an experimental drug candidate under development by Pfizer for the treatment of non-small-cell lung carcinoma. It is a selective and irreversible inhibitor of EGFR. Dacomitinib has advanced to several Phase III clinical trials. The results of the first trials were disappointing, with a failure to meet the study goals. Additional Phase III trials are ongoing (http://en.wikipedia.org/wiki/Dacomitinib).

Reference:

[1] Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS.  Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol Cancer Ther. 2012;11(9):1978-87.

[2] Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jfinne PA.  PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007;67(24):11924-32.


關(guān)鍵字: 1110813-31-4;C24H25ClFN5O2;Dacomitinib (PF29980;

公司簡介

上海一研生物科技有限公司Shanghai yiyan bio-technology Co. Ltd.主要從事免疫學(xué)、分子生物學(xué)和常規(guī)生化試劑等為一體的科研產(chǎn)品銷售企業(yè),公司自成立以來,秉承""全心全意服務(wù)于科研工作者""的企業(yè)理念,立足生物科技領(lǐng)域,運(yùn)用生物技術(shù)和科研試劑,發(fā)展現(xiàn)代生物科技,為各類大中小醫(yī)院及其它醫(yī)療機(jī)構(gòu)、高等院校、科研院所、企事業(yè)單位提供優(yōu)質(zhì)的產(chǎn)品,服務(wù)生物科技領(lǐng)域的科學(xué)研究人員。 公司具有對普通貨物、冷藏及冷凍倉庫的存儲、包裝及運(yùn)輸能力。 公司將始終堅(jiān)持信譽(yù)立業(yè)、以人為本、質(zhì)量保證、誠信服務(wù)的宗旨,不斷拼搏,開拓進(jìn)取,與各界朋友攜手共創(chuàng)美好未來。
成立日期 2014-06-05 (11年) 注冊資本 100
員工人數(shù) 50-100人 年?duì)I業(yè)額 ¥ 100萬以內(nèi)
主營行業(yè) 生化試劑,抗體,細(xì)胞培養(yǎng),分子生物學(xué),免疫安全 經(jīng)營模式 工廠,試劑
  • 上海一研生物科技有限公司
VIP 3年
  • 公司成立:11年
  • 注冊資本:100
  • 企業(yè)類型:營業(yè)執(zhí)照
  • 主營產(chǎn)品:、ELISA試劑盒、PCR檢測試劑盒、生化檢測試劑盒、標(biāo)準(zhǔn)品、抗體、細(xì)胞等
  • 公司地址:上海市閔行區(qū)莘福路2號樓
詢盤

1110813-31-4Dacomitinib (PF299804, PF299)相關(guān)廠家報價

更多
產(chǎn)品名稱 價格   公司名稱 報價日期
詢價
VIP6年
上海澤葉生物科技有限公司
2024-12-23
詢價
VIP7年
山東海沃生物科技有限公司
2024-12-23
詢價
VIP9年
滄州恩科醫(yī)藥科技有限公司
2024-12-23
詢價
VIP3年
湖北恒化科技有限公司
2024-12-23
詢價
VIP9年
武漢維斯?fàn)柭锕こ逃邢薰?/div>
2024-12-23
詢價
VIP3年
湖北魏氏化學(xué)試劑股份有限公司
2024-12-23
¥1128
VIP3年
湖北魏氏化學(xué)試劑股份有限公司
2024-12-20
¥100
VIP7年
湖北帝柏化工有限公司
2024-12-19
詢價
VIP2年
唐緣生命科學(xué)(上海)有限公司
2024-12-15
詢價
VIP2年
山東默派生物科技有限公司
2024-12-09
內(nèi)容聲明:
以上所展示的信息由商家自行提供,內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由發(fā)布商家負(fù)責(zé)。 商家發(fā)布價格指該商品的參考價格,并非原價,該價格可能隨著市場變化,或是由于您購買數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價格,請咨詢商家,以實(shí)際成交價格為準(zhǔn)。請意識到互聯(lián)網(wǎng)交易中的風(fēng)險是客觀存在的